Children and tuberculosis medicines: Bridging the research gap

Bulletin of the World Health Organization

Volumn 86, Issue 9, 2008, Pages 658-

  Hill, Suzanne ^a   Regondi, Ilaria ^a   Grzemska, Malgorzata ^a   Matiru, Robert ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION SENSITIVITY; MIXED INFECTION; PREVALENCE; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CHILD; ETHAMBUTOL; HUMANS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 50849088345     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.08.056804     Document Type: Editorial

References (2)

1. TB and children [Communicable diseases: tuberculosis fact sheet]. Geneva: WHO; 2008. Available from: http://www.searo.who.int/en/Section10/ Section2097/Section2106_10681. htm [accessed on 8 August 2008].
2. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis 2006;10:1318-30.